Stock A174900 ABCLON INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AbClon Inc.

Equities

A174900

KR7174900001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 24/06/2024 am IST 		5-day change 1st Jan Change
15,410 KRW -4.88% Intraday chart for AbClon Inc. -3.32% +3.98%
2023 AbClon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2023 AbClon Presents Non-Clon and Phase 1 Interim Results of its AT101 Novel CAR-T Therapy at the Annual 2023 AACR Conference CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,91,054 2,87,758 5,25,308 2,70,422 1,96,071 2,30,160
Enterprise Value (EV) 1 2,72,446 2,66,073 5,12,956 2,67,250 1,83,691 2,25,263
P/E ratio -166 x 56.8 x -81.6 x -26.4 x -21.2 x -17.6 x
Yield - - - - - -
Capitalization / Revenue 74.2 x 20 x 190 x 89.6 x 57.6 x 74.7 x
EV / Revenue 69.5 x 18.5 x 185 x 88.6 x 53.9 x 73.1 x
EV / EBITDA -170 x 55.6 x -94.2 x -30.3 x -25.4 x -22.9 x
EV / FCF 148 x -22.4 x -71.7 x -56 x -36.8 x -57 x
FCF Yield 0.68% -4.46% -1.4% -1.79% -2.72% -1.75%
Price to Book 15.6 x 8.18 x 19 x 14 x 5.45 x 8.66 x
Nbr of stocks (in thousands) 14,320 14,352 14,392 15,278 15,318 15,530
Reference price 2 20,325 20,050 36,500 17,700 12,800 14,820
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3,921 14,375 2,771 3,018 3,406 3,083
EBITDA 1 -1,602 4,784 -5,443 -8,835 -7,233 -9,822
EBIT 1 -1,956 4,283 -6,571 -10,229 -8,750 -11,506
Operating Margin -49.88% 29.8% -237.13% -338.93% -256.86% -373.24%
Earnings before Tax (EBT) 1 -1,796 4,704 -6,445 -10,238 -10,349 -12,755
Net income 1 -842.7 2,567 -6,445 -10,238 -9,254 -12,766
Net margin -21.49% 17.85% -232.57% -339.22% -271.66% -414.09%
EPS 2 -122.5 353.0 -447.3 -670.1 -604.5 -840.6
Free Cash Flow 1 1,841 -11,858 -7,157 -4,772 -4,997 -3,953
FCF margin 46.95% -82.49% -258.26% -158.1% -146.71% -128.22%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 18,608 21,684 12,352 3,172 12,380 4,897
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 1,841 -11,858 -7,157 -4,772 -4,997 -3,953
ROE (net income / shareholders' equity) -4.67% 9.49% -19.9% -42.1% -33.1% -40%
ROA (Net income/ Total Assets) -4.93% 7.08% -9.43% -18.3% -13% -14.5%
Assets 1 17,087 36,274 68,338 56,013 70,977 88,295
Book Value Per Share 2 1,306 2,451 1,920 1,267 2,351 1,712
Cash Flow per Share 2 483.0 240.0 101.0 50.10 346.0 789.0
Capex 1 2,361 10,555 3,441 505 75.6 45.9
Capex / Sales 60.23% 73.43% 124.16% 16.75% 2.22% 1.49%
Announcement Date 01/03/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
ABCLON INC. Stock AbClon Inc.
+3.98% 191M
CSL LIMITED Stock CSL Limited
+2.87% 94.22B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.42% 37.76B
BIOGEN INC. Stock Biogen Inc.
-13.75% 32.5B
UCB Stock UCB
+74.52% 27.75B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-11.88% 16.13B
INCYTE CORPORATION Stock Incyte Corporation
+0.49% 14.19B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.95% 11.42B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+190.36% 11.06B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.07% 9.09B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A174900 Stock
  4. Financials AbClon Inc.